Supreme Court Backs Generic Drugmaker in Patent Fight Over “Skinny Labels”
The Supreme Court unanimously rejected Amarin Pharma’s induced-infringement claim against Hikma Pharmaceuticals, clarifying that a generic drugmaker’s knowledge of possible infringing use is not enough without active steps...
